Thrivent Financial for Lutherans’s Denali Therapeutics DNLI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$837K	Hold	32,555	–	–	﹤0.01%	2079
2026 Q1	$626K	Hold	32,555	–	–	﹤0.01%	2119
2025 Q4	$538K	Sell	32,555 -3,064	-9%	-$51.7K	﹤0.01%	2223
2025 Q3	$517K	Sell	35,619 -32,298	-48%	-$464K	﹤0.01%	2068
2025 Q2	$950K	Hold	67,917	–	–	﹤0.01%	1806
2025 Q1	$924K	Sell	67,917 -25,055	-27%	-$480K	﹤0.01%	1765
2024 Q4	$1.9M	Sell	92,972 -45,890	-33%	-$1.17M	﹤0.01%	1474
2024 Q3	$4.04M	Buy	138,862 +8,358	+6%	+$207K	0.01%	1025
2024 Q2	$3.03M	Buy	130,504 +65,729	+101%	+$1.26M	0.01%	1125
2024 Q1	$1.33M	Buy	64,775 +35,093	+118%	+$660K	﹤0.01%	1720
2023 Q4	$637K	Buy	+29,682	New	+$588K	﹤0.01%	2118

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans's DNLI Position: Q2 2026 in Review

Thrivent Financial for Lutherans held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 32,555 shares worth $837K. The position accounts for ﹤0.01% of the portfolio, ranked #2079.

Thrivent Financial for Lutherans first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.04M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Thrivent Financial for Lutherans held 32,555 shares of Denali Therapeutics worth $837K as of Q2 2026.
Thrivent Financial for Lutherans left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2079 holding.
Thrivent Financial for Lutherans first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
Thrivent Financial for Lutherans's Denali Therapeutics position peaked at $4.04M in Q3 2024.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.